Table 1.
Human neutralizing mAbs against various infectious diseases.
| Miccrobe | Clone info (name) | KD (nM) | Epitope | Method | Neutralization activity | Origin | Reference info | ||
|---|---|---|---|---|---|---|---|---|---|
| Virus | SARS-CoV-2, SARS-CoV | S309 | < 1.0 × 10−3 | RBD | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro | An individual infected with SARS-CoV in 2003 | Dora Pinto et al., 2020, Nature | |
| SARS-CoV-2 | C121 | RBD | Single cell BCR DNA sequencing of Spike protein-specific B cell | in vitro | 149 COVID-19-convalescent individuals | Davide. F. Robbiani et al., 2020, Nature, and Christopher O. Barnes et al., 2020, Nature | |||
| C135 | |||||||||
| C144 | |||||||||
| SARS-CoV-2 | BD-368-2 | 0.82 | RBD | High-throughput scRNA/VDJ-seq of antigen-binding B cells | in vitro and in vivo (hACE2 transgenic mice) | 12 COVID-19 convalescent individuals from Beijing Youan Hospital | Yunlong Cao et al., 2020, Cell | ||
| SARS-CoV-2 | 311mab-31B5 | RBD | Single cell BCR DNA sequencing of RBD-specific B cell | in vitro | Recovered COVID-19 individuals | Xiangyu Chen et al., 2020, CMI | |||
| 311mab-32D4 | |||||||||
| SARS-CoV-2 | Approximal 40 clones including REGN10933 and REGN10987 | RBD | Single cell BCR DNA sequencing of RBD-specific B cell from VelocImmune mouse and human donors | in vitro | Individuals 3–4 weeks post laboratory-confirmed PCR positive test for SARS-CoV-2 and symptomatic COVID-19 infection. | Johanna Hansen et al., 2020, Science | |||
| SARS-CoV-2 | CR3022 | 6.3 | RBD | Phage display | in vitro | A convalescent SARS individual from Singapore | Jiandong Huo et al., 2020, Cell Host & Microbe, and Kaewta Rattanapist et al., 2020, Sci Rep | ||
| SARS-CoV-2 | CV30 | 3.6 | RBD | Single cell BCR-seq of Spike protein-specific B cell | in vitro | One of the first individuals infected with SARS-CoV-2 in the state of Wahington at 21 days after the onset of clinical disease | Emilie Seydoux et al., 2020 Immunity, and Nicholas K. Hurlburt et al., 2020, Nature Comm | ||
| SARS-CoV-2 | P2B-2F6 | 5.14 | RBD | Single cell BCR DNA sequencing of Spike protein-specific B cell | in vitro | 8 individuals infected with SARS-CoV-2 | Bin Ju et al., 2020, Nature | ||
| SARS-CoV-2 | S2X259 | RBD | Hybridoma (Spike protein-specific B cell and mesenchymal stromal cells) | in vitro and in vivo (Syrian hamster model) | An individual who had recovered from COVID-19 | M. Alejandra Tortorici et al., 2021, Nature | |||
| SARS-CoV-2 | 7 clones | RBD | Single cell BCR DNA sequencing of Spike protein-specific B cell | in vitro | An individual infected with SARS-CoV in 2003 | Anna Z. Wec. et al., 2020, Science | |||
| SARS-CoV-2 | COV2–2196 | RBD | Single cell BCR DNA sequencing of Spike protein-specific B cell | in vitro and in vivo (anti-IFNAR1-treated, AdV-hACE2-transduced mice) | 2 convalescing individuals who had been infected with SARS-CoV-2 in Wuhan, China | Seth J. Zost et al., 2020, Zost et al., 2020, Nature | |||
| SARS-CoV-2 | COV2–2676 | NTD | Single cell BCR DNA sequencing of Spike protein-specific B cell | in vitro and in vivo (hACE2 transgenic mice) | 2 convalescing individuals who had been infected with SARS-CoV2 in Wuhan, China | Naveenchandra Suryadevara et al., 2021, Cell | |||
| COV2–2489 | |||||||||
| SARS-CoV-2 | P5A-3C8 | 1.3 | RBD (K417/R/A/E/N/T) | Single cell BCR DNA sequencing of Spike protein-specific B cell | in vitro and in vivo (Syrian hamster model) | 8 individuals infected with SARS-CoV2 | Qi Zhang et al., 2021, Nature Comm | ||
| SARS-CoV-2 | 7 clones | RBD | Single cell BCR DNA sequencing of Spike protein-specific B cell and these B cells immortalized | in vitro | 4 individuals in North America with recent laboratory-confirmed symptomatic SARS-CoV-2 infections | Seth J. Zost, Gilchuk, Case, et al., 2020, Zost, Gilchuk, Chen, et al., 2020, Nature medicine | |||
| H1N1 influenza virus | 1F1 | 5.4 | HA | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro and in vivo (BALB/c mice model) | Survivors of 1918 H1N1 influenza virus pandemic | Xiaocong Yu, et al., 2008, Nature | ||
| 1 l20 | 0.048 | ||||||||
| 2B12 | 6.2 | ||||||||
| 2D1 | 0.25 | ||||||||
| 4D20 | 0.14 | ||||||||
| H5N1 and H1N1 influenza viruses | CR6261 | 3.8 (Fab) | H1 HA | Phage display | in vitro and in vivo (BALB/c mice model) | Volunteers recently vaccinated with the seasonal influenza vaccine | Mark Throsby et al., 2008, PLoS ONE | ||
| 4.1(Fab) | H5 HA | ||||||||
| Influenza A and B viruses | CR9114 | 1.3–4.8 | B HA | Phage display | in vitro and in vivo (Mouse model) | Volunteers recently vaccinated with the seasonal influenza vaccine | Cyrille Drefus, et al., 2012, Science | ||
| 0.9–2.2 | A HA | ||||||||
| H7N9 influenza virus | NA-80 | 0.17 | NA (N9) | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro and in vivo (BALB/c mice model) | H7N9 survivors | Iuliia M. Gilchuk et al., 2019, Cell Host & Microbe | ||
| NA-22 | 0.81 | ||||||||
| H1N1 and H3N2 influenza viruses | MEDI8852 | HA of all 16 subtypes | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro and in vivo (Mouse model) | Volunteers recently vaccinated with the seasonal influenza vaccine | Nicole L. Kallewaard et al., 2016, Cell | |||
| H1N1 and H1N5 influenza viruses | 70-1F02 | 0.00749 | H1N1 HA | Single cell BCR DNA sequencing of HA-specific plasmablasts | in vitro and in vivo (BALB/c mice model) | 24 healthy adults immunized with the subunit pH1N1 2009 vaccine | Gui-Mei Li et al., 2012, PNAS, and Raffael Nachbagauer et al., 2018, JV | ||
| 0.0104 | H1N5 HA | ||||||||
| 9-3A01 | 0.179 | H1N1 HA | |||||||
| 0.718 | H1N5 HA | ||||||||
| H1 influenza virus | KPF1 | 0.178 | HA | Single cell BCR DNA sequencing of HA-specific plasmablasts | in vitro and in vivo (C57BL/6 mice model) | A healthy subject prior to seven days and one month after receiving the 2014–2015 seasonal inactivated quadrivalent influenza vaccine (A/California/07/2009 (H1N1) pdm09-like virus, A/Texas/50/2012 (H3N2)-like virus, B/ Massachusetts/2/2012-like virus, B/Brisbane/60/2008-like virus) as standard-of-care at the University of Rochester Medical Center | Aitor Nogales et al., 2018, Sci Rep | ||
| H7N9 infulenza virus | H7.5 | <0.1(Fab) | HA (head) | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro | Donors who participated in a vaccination trial with monovalent, inactivated influenza (H7N9), A/Shanghai/02/2013 vaccine candidate (DMID13–0033) | Hannah L. Turner et al., 2019, PLOS Biology | ||
| H7N9 infulenza virus | 5 clones | HA | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro and in vivo (BALB/c mice model) | Donors who participated in a multicenter trial conducted by the NIH Vaccine Treatment and Evaluation Unit (DMID13–0033) | Natalie J. Thornburg et al., 2016, JCI | |||
| H3N2 infulenza virus | C585 | < 1.00–4.01 × 10−3 | HA | Antibody-encoding gene sequencing of plasmablasts | in vitro | A healthy, 56-year-old male vaccinated in the 2013/2014 season with TIV composed of A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 (Yamagata lineage) | Yu Qiu et al., 2020, JV | ||
| Infulenza H3N2 variant virus | H3v-47 | < 1.0 × 10−3 | HA (H3N2v) | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro and in vivo (DBA/2 J mice model) | Donors vaccinated with an experimental H3N2v vaccine containing the A/Minnesota/11/ 2010 strain | Sandhya Bangaru et al., 2018, Nature comm | ||
| Infulenza H3N2 variant virus | 6 clones | HA | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro and in vivo (DBA/2 J mice model) | Healthy adult donors received 2 doses of subvirion H3N2v vaccine (15 μg of HA/dose) 21 days apart in an open–label trial |
Sandhya Bangaru et al., 2016, JCI insight. | |||
| Group1 and Group 2 Infulenza A viruses | Fl6 | HA of all 16 subtypes | Single cell antibody-encoding gene sequencing of plasma cells | in vitro and in vivo (BALB/c mice and ferret models) | Healthy donors seven days after i.m. vaccination with seasonal influenza vaccine according to manufacturer instructions |
Davide Corti et al., 2011, Science | |||
| EBOV | mAb114 | GP | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro and in vivo (rhesus macaques model) | Two survivors of the 1995 EVD outbreak in Kikwit | Davide Corti et al., 2016, Science | |||
| EBOV | EBOV-526 | GP | Human hybridoma | in vitro and in vivo (STAT1 KO mice, guinea pigs and ferrets models) | Two survivors of the 2014 EVD outbreak in the DRC and one survivor of the West African 2013–2016 EVD epidemic | Pavlo Gilchuk et al., 2018, Immunity | |||
| EBOV-515 | |||||||||
| EBOV, BDBV and SUDV | EBOV-548 | The base region of GP | Human hybridoma | in vitro and in vivo (BALB/c mice and rhesus macaques models) | Two human survivors of the 2014 EVD outbreak in the DRC and one survivor of the West African 2013–2016 EVD epidemic | Pavlo Gilchuk et al., 2020, Immunity | |||
| EBOV-520 | The gyycan cap of GP | ||||||||
| EBOV and BDBV | BDBV223 | GP2 stalk | Human hybridoma | in vitro and in vivo (BALB/c mice model) | A human survivor of the 2007 BDBV outbreak in Uganda | Andrew I.Flyak, er al., 2016, Cell, Andrew I. Flayk, et al., 2018, Nature microbe, FlyakLiam B. King, et al., 2019, Nature comm | |||
| EBOV | Several clones | GP | Single cell BCR DNA sequencing of GP-specific B cell | in vitro and in vivo (BALB/c mice model) | Human survivors of the 2014 EBOV Zaire outbreak. |
Zachary A. Bornholdt et al., 2016, Science | |||
| EBOV and BDBV | Several clones | The fusion loop region of GP | Yeast display | in vitro and in vivo (mouse and ferret models) | Human survivors of the 2014 EBOV Zaire outbreak. |
Anna Z. Wec. et al., 2017, Cell | |||
| HCV | 2A5 | GT1b E2 region (conformation-dependent) | Human hybridoma | in vitro and in vivo (Human liver-chimeric mice model) | An individual chronically infected with HCV | Isabelle Desombere et al., 2017, Antiviral Res | |||
| HCV | AR4A | 2.9 ± 1.8 | outside the CD81-binding site on the E1E2 complex | Phage display | in vitro | A 35-year-old female individual with Sjögren's syndrome and chronic HCV (GT1a) infection | Erick Giang et al., 2012, PNAS, and Rodrigo Velazquez-Moctezuma, et al., 2018, JID | ||
| HCV | AR3A | 1.3/1.7 | E2 (HCVpp GT1a/2a/4/5) | Phage display | in vitro and in vivo (Human liver-chimeric mice model) | A 35-year-old female individual with Sjögren's syndrome and chronic HCV (GT1a) infection | Mansun Law et al., 2008, Nature medicine | ||
| AR3B | 2.0/2.3 | ||||||||
| HBV | 3 clones | HBsAg | Antibody-encoding gene sequencing and cloning of HBsAg specific B cells immortalized by EBV | in vitro | A vaccinated healthy donor and a individual convalescing from acute HBV infection | Antonella Cerio, et al., 2015, PLoS ONE | |||
| ZIKV | ZIKV-117 | E protein | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro and in vivo (IFNAR-blocking C57BL/6 mice model) | Healthy individuals who had previously been infected with ZIKV in diverse geographic locations. | Gopal Sapparapu et al., 2016, Nature, S. Saif Hsaan, et al., 2017, Nature comm, and Jesse H. Erasmus et al., 2020 Methods & Clinical Development | |||
| ZIKV | 2F-8 | E protein (DIII) | Phage display | in vitro and in vivo (Ifnar−/− mice model) | Two ZIKV-infected individuals at Seoul National University Hospital | Sang Il Kim et al., 2021, BBRC | |||
| ZIKV | ZIKV-195 | E protein | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro and in vivo (IFNAR-blocking C57BL/6 mice model) | Healthy individuals who had previously been infected with ZIKV in diverse geographic locations. | Feng Long et al., 2019, PNAS | |||
| ZIKV | ZKA64 | E (DI/II) | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro and in vivo (A129 mice model) | Four ZIKV- infected individuals from the current epidemic, of which two were DENV-naïve and two had serological records of DENV infection | Karin Stettler et al., 2016, Science | |||
| ZIKV and DENV | MZ4 | 2.7/2.6 | E protein (DI/III linker region) (ZIKV/DENV2) | Single cell BCR DNA sequencing of ZIKV E protein- and DENV E protein-specific B cells | in vitro and in vivo (ZIKV challenge: BALB/c mice model, DENV-2 challenge: Ifnar−/− mice model) | A flavivirus-experienced individual enrolled in the ZPIV phase 1 vaccine clinical trial (NCT02937233) conducted at Beth Israel Deaconess Medical Center | Vincent Dussupt et al., 2020, Nature medicine | ||
| DENV | m366.6 | 0.27–1.9 | E protein (DIII) | Phage display | in vitro and in vivo (A129 mice model) | Individual who might have been infected during foreigntravel. | Dan Hu et al., 2019, PLOS Pathogen | ||
| Parasite | Malaria | CIS43 | 42 | PfCSP | Single cell antibody-endocing gene sequencing of PfCSP-specific plasmablasts | in vitro and in vivo (C57BL/6 mice model) | A malaria-naive individual who received the PfSPZ vaccine | Neville K Kisalu et al., 2018, Nature medicine and Lawrence T. Wang et al., 2020, Immunity | |
| Bacteria | Toxin | Clostridium tetani | 8A7 | TeNT (Hc) | Antibody-encoding gene sequencing and cloning of Memroy B cells immortalized by EBV | in vitro and in vivo (Mouse model) | A healthy individual belonging to a presumed population that has been vaccinated against tetanus | Takeharu Minamitani et al., 2021, Sci Rep | |
| 17F7 | TeNT (Hc) | ||||||||
| 8D8 | TeNT (Hn) | ||||||||
| 16E8 | TeNT (Lc + Hn + Hc) | ||||||||
| Clostridium botulinum | Three clones | 0.24–14.33 (scFv) | BTX Lc | Yeast display | in vitro | A healthy individual immunized with BONT/A-E Toxoid | Yongfeng Fan et al., 2015, toxins | ||
| Corynebacterium diphtheriae | Several clones | DT | Phage display | In vitro | Three individuals received a regular booster immunization with an adsorbed diphtheria and tetanus vaccine | Esther Veronika Wenzel et al., 2020, Sci Rep | |||
| Bacterial components | Pseudomonas aeruginosa | Cam-003 | 144 | Exopolysaccharide Psl | Phage display | in vitro and in vivo (Mouse model) | Healthy individuals and patients convalescing from P. aeruginosa infections | Antonio DiGiandomenico et al., 2012, JEM | |
| Staphylococcus aureus | 514G3 | 0.0467 | SpA | Phage display | in vitro and in vivo | Healthy individuals | Avanish K. Varshney et al., 2018, PLOS one | ||
ACE2, angiotensin-converting enzyme 2; AdV-hACE2, replication-defective adenoviruses encoding human ACE2; BCR, B cell receptor; BDBV, Bundibugyo ebolavirus; BTX, botulinum neurotoxin; SUDV, Sudan ebolavirus; COVID-19, Coronavirus Disease 2019; DENV, Dengue virus; DRC, Democratic Republic of the Congo; DT, Diphtheria toxin; EBV, Epstein-Barr virus; EBOV, Ebola virus; EVD, Ebola virus disease; Fab, Fab, fragmented antigen binding region; GP, glycoprotein; GT, genotype; HA, hemagglutinin; HBsAg, hepatitis B virus antigen; HBV, hepatitis B virus, Hc, heavy chain C-terminal receptor binding domain; HCV, hepatitis C virus; HCVpp, pseudotype virus particles HCV; Hn, heavy chain N-terminal translocation domain, IFNAR1, interferon Alpha and Beta receptor subunit 1; IFNR, interferon receptor; i.m., intramuscular injection; KD, dissociation constant; Lc, light chain; NA, neuraminidase; NTD, N-terminal domain; PCR, polymerase chain reaction; PfSPZ, Plasmodium falciparum sporozoite; SARS-CoV, severe acute respiratory syndrome coronavirus; SpA, S. aureus wall moiety Protein A; TeNT, tetanus toxin; TIV, trivalent inactivated influenza vaccine; RBD, receptor binding domain; ZIKV, Zika virus; ZPIV, Z001 Zika purified inactivated virus (Bangaru et al., 2016; Bangaru et al., 2018; Barnes et al., 2020; Bornholdt et al., 2016; Cao et al., 2020; Cerino, Bremer, Glebe, & Mondelli, 2015; Chen et al., 2020; Corti et al., 2011; Corti et al., 2016; Desombere et al., 2017; DiGiandomenico et al., 2012; Dreyfus et al., 2012; Dussupt et al., 2020; Erasmus et al., 2020; Fan et al., 2015; Flyak et al., 2016; Flyak et al., 2018; Giang et al., 2012; Gilchuk et al., 2018; Gilchuk et al., 2019; Hansen et al., 2020; Hasan et al., 2017; Hu et al., 2019; Huo et al., 2020; Hurlburt et al., 2020; Ju et al., 2020; Kallewaard et al., 2016; Kim et al., 2021; Kisalu et al., 2018; Law et al., 2008; Li et al., 2012; Long et al., 2019; Minamitani et al., 2021; Nachbagauer et al., 2018; Nogales et al., 2018; Pinto et al., 2020; Qiu et al., 2020; Rattanapisit et al., 2020; Robbiani et al., 2020; Sapparapu et al., 2016; Seydoux et al., 2020; Stettler et al., 2016; Suryadevara et al., 2021; Thornburg et al., 2016; Throsby et al., 2008; Tortorici et al., 2021; Turner et al., 2019; Varshney et al., 2018; Velázquez-Moctezuma et al., 2018; Wang et al., 2020; Wec et al., 2017; Wec et al., 2020; Wenzel et al., 2020; Yu, Tsibane, et al., 2008; Zhang et al., 2021; Zost, Gilchuk, Case, et al., 2020; Zost, Gilchuk, Chen, et al., 2020).